
 **2nd Annual Michigan Liver Cancer Consortium (4/23/25) | 04/23/2025 5:30 PM Townsend Hotel (Birmingham)**

An interactive program to learn key updates in the evaluation and management of liver cancer and engage in active case discussions with local experts in the field. This is a multi-disciplinary program for physicians, APPs, nursing, and learners of all levels. Experts in Hepatobiliary Surgery, Medical Oncology, Hepatology, Interventional Radiology, Diagnostic Radiology, and Radiation Oncology from around the state will interact to discuss current up-to-date management strategies and challenges that clinicians face in the care of patients with liver cancer.

**Program Goal**

1 To understand the latest data and approved therapies for systemic therapy in hepatocellular carcinoma management.

2 To learn about locoregional therapies for treatment of liver cancer, and strategies to choose specific therapies.

3 To discuss when to consider combination therapy utilizing liver-directed treatment along with systemic therapy for improved outcomes.

4 To collaborate with colleagues at other local institutions and learn about available options for treatment of liver cancer and clinical trial options for patients.

5 To review the patient best suited for surgical resection and/or liver transplant for liver cancer.

6 To discuss current approaches to using radiation therapy for patients with hepatocellular carcinoma.

7 To understand the latest diagnosis and management strategies for cholangiocarcinoma and the multidisciplinary approach to care of this condition.

8 To learn the latest radiology interpretation of cross-sectional imaging after liver cancer therapies based on the LIRADS criteria updates.

9 To understand the expanded indications for liver transplant for liver cancer.

**Target Audience** Hematology Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sumit Singla, MD | Faculty | Consulting Fee-Boston Scientific - 09/23/2024 |
| Shunji Nagai, MD | Faculty | Nothing to disclose - 06/06/2024 |
| Reena Salgia, MD, FAASLD | Course Director, Faculty | Advisor-Eisai (Relationship has ended)|Advisor-Exelixis (Relationship has ended)|Advisor-Astrazeneca (Relationship has ended)|Advisor-Cook Medical (Relationship has ended) - 01/15/2025 |
| Giordano Mitchell, MD | Faculty | Nothing to disclose - 01/31/2025 |
| Christina Miller, BS | CME Specialist | Nothing to disclose - 01/29/2025 |
| Parag Parikh, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Nuvaira - 01/13/2025 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/07/2025 |
| Christopher J Sonnenday, MD, MPH | Faculty | Nothing to disclose - 01/31/2025 |
| Tami O'connor | Activity Coordinator | Nothing to disclose - 01/16/2025 |
| Vaibhav Sahai, MBBS | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Autem Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Amplity (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Delcath Systems (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Histosonics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ipsen|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Elevar|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Jazz|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Servier|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Taiho Pharmaceutical (Relationship has ended)|Grant or research support-Actuate|Grant or research support-Jazz|Grant or research support-BMS|Grant or research support-Clovis Oncology (Relationship has ended)|Grant or research support-Cornerstone|Grant or research support-Exelixis (Relationship has ended)|Grant or research support-Fibrogen|Grant or research support-Ipsen|Grant or research support-Medimmune (Relationship has ended)|Grant or research support-Relay|Grant or research support-Repare|Grant or research support-Syros (Relationship has ended)|Other: Material (drugs) for lab work-Beigene (Relationship has ended)|Advisor-Servier|Grant or research support-Boehringer Ingelheim|Honoraria-Dava Oncology (Relationship has ended)|Grant or research support-Elicio|Grant or research support-Esanik|Grant or research support-Transthera - 01/15/2025 |
| Maria Diab, MD | Faculty | Advisor-Novartis|Grant or research support-BMS|Grant or research support-Gilead|Advisor-Astrazeneca (Relationship has ended) - 03/13/2025 |
| Neehar Parikh, MD | Faculty | Consulting Fee-Astrazeneca|Consulting Fee-Exact Sciences|Advisor-Genentech (Relationship has ended)|Consulting Fee-Exelixis - 04/04/2025 |
| Mishal Mendiratta-Lala, MD | Faculty | Nothing to disclose - 04/28/2024 |
| Eliza W Beal, MD | Faculty | Nothing to disclose - 01/20/2025 |
| Amanda Su, MD | Co-Director | Nothing to disclose - 01/29/2025 |
| Thomas Quinn, MD | Faculty | Nothing to disclose - 01/15/2025 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 2.50 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Please allow a minimum of 3 days to process this request.